Sugi Predict

Sugi Predict / Compounds / SCHEMBL1107142

SCHEMBL1107142

SCHEMBL1107142

COC(=O)Cc1ccc(C)cc1

nearest known ligand 0.66

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ CYP4F2 P78329 1/20 0.66
▸ CYP4A11 Q02928 1/20 0.66
▸ HSP90AB1 P08238 1/20 0.53
▸ GAA P10253 2/20 0.53
▸ ALDH1A1 P00352 2/20 0.53
▸ GFER P55789 1/20 0.53
▸ MAPT P10636 3/20 0.52
▸ MAPK1 P28482 1/20 0.52
▸ NPC1 O15118 3/20 0.51
▸ RAB9A P51151 3/20 0.51
▸ SMN1; SMN2 Q16637 3/20 0.51
▸ HPGD P15428 3/20 0.50
▸ L3MBTL1 Q9Y468 3/20 0.50
▸ TDP1 Q9NUW8 2/20 0.50
▸ LMNA P02545 1/20 0.49
▸ TP53 P04637 1/20 0.49
▸ KMT2A Q03164 1/20 0.49
▸ CTBP2 P56545 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL28854172 0.98 CYP4F2 (0.63) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
Nitrogen SCHEMBL27903948 0.96 CYP4F2 (0.61) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
SCHEMBL15804409 0.94 CYP4F2 (0.59) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
SCHEMBL4113212 0.91 CYP4F2 (0.76) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
SCHEMBL15581442 0.91 CYP4A11 (0.66) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
SCHEMBL31324186 0.91 CYP4F2 (0.56) CYP4F2CYP4A11GAAALDH1A1MAPT
SCHEMBL6795893 0.86 TDP1 (0.50) CYP4F2CYP4A11GAAALDH1A1MAPT
Toluene SCHEMBL27935015 0.86 KMT2A (0.57) CYP4F2CYP4A11HSP90AB1ALDH1A1MAPK1
SCHEMBL14422859 0.85 CYP4F2 (0.63) CYP4F2CYP4A11HSP90AB1GAAALDH1A1
SCHEMBL6455146 0.84 KMT2A (0.50) CYP4F2CYP4A11MAPTNPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 367 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108997188-B Synthetic method of erexib 苏州富士莱医药股份有限公司 2021-08-31 — — CN claimed
CN-110669042-A Preparation method and application of phentriazine compound used as polyvinyl chloride light stabilizer 河南龙湖生物技术有限公司 2020-01-10 — — CN claimed
CN-108997188-A The synthetic method of imrecoxib 苏州富士莱医药股份有限公司 2018-12-14 — — CN claimed
CN-102382056-B Preparation method of 5-hydroxyl-substituted pyrazole SINOCHEM CORP 2015-04-22 — — CN claimed
CN-1893910-A Cyclic siloxane compositions for active ingredient release GEN ELECTRIC (US) 2007-01-10 — — CN claimed
JP-57053730-A — — None — — JP disclosed
EP-4721737-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES Scinnohub Pharmaceutical Co., Ltd. (CN) 2026-04-08 — — EP disclosed
US-20250282749-A1 COMPOUNDS AND METHODS OF USE TANGO THERAPEUTICS, INC. 2025-09-11 — — US disclosed
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE SCINNOHUB PHARMACEUTICAL CO., LTD. (CN) 2025-05-08 — — US disclosed
US-12264169-B2 Heteroaryl inhibitors of PDE4 Tetra Discovery Partners (US) 2025-04-01 — — US disclosed
WO-2024245143-A1 USE OF PHARMACEUTICAL COMPOSITION COMPRISING COMPOUND HAVING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE FOR TREATING ANEMIA-RELATED DISEASES 赛诺哈勃药业（成都）有限公司 2024-12-05 — — WO disclosed
EP-4469445-A1 COMPOUNDS AND METHODS OF USE Tango Therapeutics, Inc. (US) 2024-12-04 — — EP disclosed
US-4288364-A REACTING A 3-/2-HYDROXYIMINOACETYLAMINO/-2-OXOAZETIDINE WITH AN ORGANIC CARBONATE OR ACYL HALIDE CIBA-GEIGY CORPORATION (US) 1981-09-08 — — US disclosed
EP-0005507-A1 Process for the fragmentation of 3-(2-hydroxyimino-acetylamino)-2-oxo azetidin compounds and compounds obtained thereby CIBA-GEIGY AG (CH) 1979-11-28 — — EP disclosed
US-4142054-A TRIVALENT THALLIUM SALT THE UPJOHN COMPANY (US) 1979-02-27 — — US disclosed
US-4135051-A ENOL ETHER OF AN ARYL ALKYL KETONE WITH A THALLIJM SALT, REGENERATION OF THALLIUM SALT BY ADDING PERACID AND REACTIVE METAL COMPOUND THE UPJOHN COMPANY (US) 1979-01-16 — — US disclosed
US-4107439-A Process for preparing arylalkanoic acid derivatives THE UPJOHN COMPANY (US) 1978-08-15 — — US disclosed
US-4060690-A COBALT CONTAINING CATALYST DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1977-11-29 — — US disclosed
US-3993437-A Process for the dyeing of polyamide fibers with sulphur dyestuffs CASSELLA FARBWERKE MAINKUR AKTIENGESELLSCHAFT (DT) 1976-11-23 — — US disclosed
US-3974202-A CARBON MONOXIDE, BENZYL HALIDE AND AN ALCOHOL; COBALT OR IRON CARBONYL CATALYST DYNAMIT NOBEL AKTIENGESELLSCHAFT (DT) 1976-08-10 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250145635-A1 COMPOUND CONTAINING BIS(AZANYLYLIDENE) SULFONYL STRUCTURE AND USE THEREOF IN MEDICINE BCL9, USP9X, BCL9L CYP4F2 4431/4885CYP4A11 3759/4885HSP90AB1 1600/4885
US-20250282749-A1 COMPOUNDS AND METHODS OF USE CYP1B1, CYP2C19, UGT1A1 CYP4F2 69/4885CYP4A11 31/4885HSP90AB1 2232/4885
US-12264169-B2 Heteroaryl inhibitors of PDE4 PDE4A, PDE4B, PDE4C CYP4F2 495/4885CYP4A11 60/4885HSP90AB1 1414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.